Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.

Vaccine - 21 May 2012

Parra Gabriel I, Bok Karin, Taylor Ross, Haynes Joel R, Sosnovtsev Stanislav V, Richardson Charles, Green Kim Y

Abstract excerpt

Noroviruses, a major cause of acute gastroenteritis worldwide, present antigenic diversity that must be considered for the development of an effective vaccine. In this study, we explored approaches to increase the broad reactivity of virus-like particle (VLP) norovirus vaccine candidates. The immunogenicity of a GII.4 "Consensus" VLP that was engineered from sequences of three genetically distinct naturally...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross Reactions

Share to Injections, Intramuscular

Share to Norovirus

Share to Vaccination

Share to Vaccines, Synthetic

Share to Viral Vaccines

Source

Open in PubMed Open full text

Identifiers

PMID: 22469864
DOI: 10.1016/j.vaccine.2012.03.050
PMCID: PMC3359014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.PMID 22469864Read ↗

Chimeric GII.4 Norovirus Virus-Like-Particle-Based Vaccines Induce Broadly Blocking Immune ResponsesSemantic proximity Read ↗

Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.Semantic proximity Read ↗

Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.Semantic proximity Read ↗

Integrated in-silico design and in vivo validation of multi-epitope vaccines for norovirusSemantic proximity Read ↗

Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial.Semantic proximity Read ↗

Receptor profile and immunogenicity of the non-epidemic norovirus GII.8 variant.Semantic proximity Read ↗

Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults.Semantic proximity Read ↗

Variable and conserved B cell epitopes of GII.4 human noroviruses.Semantic proximity Read ↗

Norwalk virus-like particles as vaccinesSemantic proximity Read ↗

Manipulation of immunodominant variable epitopes of norovirus capsid protein elicited cross-blocking antibodies to different GII.4 variants despite the low potency of the polyclonal sera.Semantic proximity Read ↗

Chimeric virus-like particles of human norovirus constructed by structure-guided epitope grafting elicit cross-reactive immunity against both GI.1 and GII.4 genotypes.Semantic proximity Read ↗

Antigenic Relatedness of Norovirus GII.4 Variants Determined by Human Challenge Sera.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.